The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

På svenska

Author

  • Roland Kolbeck
  • Alexander Kozhich
  • Masamichi Koike
  • Li Peng
  • Cecilia K Andersson
  • Melissa M. Damschroder
  • Jennifer L. Reed
  • Robert Woods
  • William W. Dall'Acqua
  • Geoffrey L. Stephens
  • Jonas Erjefält
  • Leif Bjermer
  • Alison A. Humbles
  • David Gossage
  • Herren Wu
  • Peter A. Kiener
  • George L. Spitalny
  • Charles R. Mackay
  • Nestor A. Molfino
  • Anthony J. Coyle
Show all

Summary, in English

Background: Peripheral blood eosinophilia and lung mucosal eosinophil infiltration are hallmarks of bronchial asthma. IL-5 is a critical cytokine for eosinophil maturation, survival, and mobilization. Attempts to target eosinophils for the treatment of asthma by means of IL-5 neutralization have only resulted in partial removal of airway eosinophils, and this warrants the development of more effective interventions to further explore the role of eosinophils in the clinical expression of asthma. Objective: We sought to develop a novel humanized anti IL-5 receptor alpha (IL-5R alpha) mAb with enhanced effector function (MEDI-563) that potently depletes circulating and tissue. resident eosinophils and basophils for the treatment of asthma. Methods: We used surface plasmon resonance to determine the binding affinity of MEDI-563 to Fc gamma RIII alpha. Primary human eosinophils and basophils were used to demonstrate antibody-dependent cell-mediated cytotoxicity. The binding epitope of MEDI-563 on IL-5R alpha was determined by using site-directed mutagenesis. The consequences of MEDI-563 administration on peripheral blood and bone marrow eosinophil depletion was investigated in nonhuman primates. Results: MEDI-563 binds to an epitope on IL-5R alpha that is in close proximity to the IL-5 binding site, and it inhibits IL-5 mediated cell proliferation. MEDI-563 potently induces antibody-dependent cell-mediated cytotoxicity of both eosinophils (half-maximal effective concentration = 0.9 pmol/L) and basophils (half-maximal effective concentration = 0.5 pmol/L) in vitro. In nonhuman primates MEDI-563 depletes blood eosinophils and eosinophil precursors in the bone marrow. Conclusions: MEDI-563 might provide a novel approach for the treatment of asthma through active antibody-dependent cell-mediated depletion of eosinophils and basophils rather than through passive removal of IL-5. (J Allergy Clin Immunol 2010;125:1344-53.)

Publishing year

2010

Language

English

Pages

1344-1353

Publication/Series

Journal of Allergy and Clinical Immunology

Volume

125

Issue

6

Document type

Journal article

Publisher

Elsevier

Topic

  • Respiratory Medicine and Allergy

Keywords

  • IL-5
  • IL-5 receptor
  • monoclonal antibody
  • basophil
  • Fc
  • gamma RIII alpha
  • antibody-dependent cell-mediated cytotoxicity
  • Asthma
  • eosinophil

Status

Published

Research group

  • Airway Inflammation and Immunology

ISBN/ISSN/Other

  • ISSN: 1097-6825